Ki-67(MIB-1), Breast, Semi-Quantitative Immunohistochemistry, Manual
Use
Determining proliferation of tumor cells in paraffin-embedded tissue blocks from patients diagnosed with breast carcinoma. Ki-67 (MIB-1 clone) is a monoclonal antibody that reacts with cells undergoing DNA synthesis by binding to the Ki-67 antigen, a marker known to be expressed only in proliferating cells. By measuring the amount of tumor cells expressing Ki-67, an estimate of DNA synthesis can be determined. This analysis may provide useful prognostic information in various tumor types.
Special Instructions
Ki-67 immunohistochemistry testing on intracystic papillary carcinoma and solid papillary carcinoma, without clearly stating invasive carcinoma, is not appropriate and will be canceled without processing. Attach the green pathology address label included in the kit to the outside of the transport container. Pathologist's name, address, and phone number are required. Include accompanying pathology report stating the final diagnosis. If not available, a preliminary diagnosis is acceptable only if it refers to invasive or metastatic breast carcinoma.
Limitations
The paraffin block analyzed must be representative of the patient's tumor. Test results should be interpreted in the context of clinical findings and other laboratory data.
New York Approved
Methodology
Immunoassay (IHC)
Biomarkers
LOINC Codes
- 85330-9
- 85330-9
- 19139-5
- 81178-6
- 44638-5
- 21918-8
- 62364-5
- 80398-1
Result Turnaround Time
4-6 days
Related Documents
For more information, please review the documents below
Specimen
Tissue (FFPE)
Volume
Not provided
Minimum Volume
Not provided
Container
Pathology Packaging Kit (T554)
Collection Instructions
Submit paraffin-embedded invasive or metastatic breast carcinoma tissue. Attach the green pathology address label included in the kit to the outside of the transport container.
Causes for Rejection
No specimen should be rejected.